Zacks Investment Research downgraded shares of GENTIUM SPA-ADR (GENT) from OUTPERFORM to NEUTRAL on December 26, 2012, with a target price of $13.50.
Gentium, S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the research, development and manufacture of drugs to treat and prevent a variety of vascular diseases and conditions related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Track Designation by the U.S. FDA for the treatment of Severe VOD, Orphan Drug status by the U.S. FDA for the treatment and prevention of VOD and Orphan Medicinal Product Designation by the European Commission for the treatment and prevention of VOD.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on GENTIUM SPA-ADR (GENT),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment